
|Articles|December 1, 2001
New monoclonal antibody selectively targets PCa sites
New York-A newer monoclonal antibody is showing a canny ability to target prostate cancer cells in both bony and soft tissue, and its therapeutic potential is now undergoing testing. Neil Bander, MD, and colleagues from New York Presbyterian-Weill Cornell Medical Center developed the antibody, dubbed J591 (licensed by BZL Biologics, Inc., Framingham, MA, and sub-licensed by Millennium Pharmaceuticals, Cambridge, MA).
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
Andrea B. Apolo, MD, discusses survival gains with EV/pembrolizumab in bladder cancer
3
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
4
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
5